CeriBell (NASDAQ:CBLL) Hits New 52-Week High – Here’s What Happened

CeriBell, Inc. (NASDAQ:CBLL)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $24.44 and last traded at $24.40, with a volume of 396312 shares changing hands. The stock had previously closed at $23.33.

Analyst Ratings Changes

A number of research firms recently issued reports on CBLL. BTIG Research increased their price target on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday. Barclays upgraded CeriBell to a “neutral” rating in a research report on Tuesday. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Finally, Canaccord Genuity Group increased their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.40.

CeriBell Trading Down 0.8%

The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. The company has a market cap of $929.18 million, a P/E ratio of -13.76 and a beta of 0.81. The stock has a 50-day moving average of $19.17 and a two-hundred day moving average of $19.13.

CeriBell (NASDAQ:CBLL) last released its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The company had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. On average, equities research analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Insider Activity at CeriBell

In other news, Director William W. Burke sold 2,207 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total value of $43,786.88. Following the transaction, the director owned 23,022 shares in the company, valued at approximately $456,756.48. This represents a 8.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Joseph Michael Taylor sold 13,095 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $23.40, for a total transaction of $306,423.00. Following the sale, the director directly owned 48,478 shares of the company’s stock, valued at $1,134,385.20. This trade represents a 21.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 313,780 shares of company stock worth $6,241,749 in the last ninety days. 17.70% of the stock is currently owned by company insiders.

Institutional Trading of CeriBell

A number of institutional investors and hedge funds have recently modified their holdings of CBLL. Strs Ohio purchased a new stake in shares of CeriBell during the first quarter valued at $27,000. Caitong International Asset Management Co. Ltd raised its position in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in CeriBell during the 3rd quarter valued at about $33,000. CWM LLC boosted its holdings in shares of CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.